| Entry |
|
|---|
| Name |
Infliximab (USAN/INN);
Infliximab (genetical recombination) (JAN);
Infliximab (genetical recombination) [Infliximab biosimilar 1] (JAN);
Infliximab (genetical recombination) [Infliximab biosimilar 2] (JAN);
Infliximab (genetical recombination) [Infliximab biosimilar 3] (JAN);
Infliximab-dyyb;
Infliximab-abda;
Infliximab-axxq;
Remicade (TN);
Inflectra (TN);
Renflexis (TN);
Avsola (TN) |
|---|
| Product |
|
|---|
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
|
|---|
| Remark |
| Therapeutic category: | 2399 |
|
|---|
| Efficacy |
Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody |
|---|
| Disease |
Crohn's disease [DS: H00286] Ulcerative colitis [DS: H01466] Rheumatoid arthritis [DS: H00630] Ankylosing spondylitis [DS: H01674] Psoriatic arthritis [DS: H01507] Plaque psoriasis [DS: H01656] |
|---|
| Type |
Monoclonal antibody |
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04612 | Antigen processing and presentation |
| hsa04920 | Adipocytokine signaling pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB02 Infliximab
D02598 Infliximab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunosuppressants
Tumor Necrosis Factor (TNF) Blockers
Infliximab
D02598 Infliximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
239 Miscellaneous
2399 Others
D02598 Infliximab (USAN/INN); Infliximab (genetical recombination) (JAN); Infliximab (genetical recombination) [Infliximab biosimilar 1] (JAN); Infliximab (genetical recombination) [Infliximab biosimilar 2] (JAN); Infliximab (genetical recombination) [Infliximab biosimilar 3] (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
D02598 Infliximab
Drug classes [BR:br08332]
Immunological agent
DG01936 TNF inhibitor
D02598 Infliximab
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D02598 Infliximab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D02598 Infliximab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02598
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02598
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
